The potential use of peptides and vaccination to treat systemic lupus erythematosus

Current Opinion in Rheumatology

Volumn 12, Issue 5, 2000, Pages 399-406

  Singh, Ram Raj ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; RIBONUCLEOPROTEIN;

ANTIBODY PRODUCTION; B LYMPHOCYTE; EPITOPE MAPPING; HELPER CELL; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE ACTIVATION; MOUSE; NEPHRITIS; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PEPTIDES; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION; VACCINES, SUBUNIT;

EID: 0033840040     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200009000-00008     Document Type: Review

References (61)

1. Novel treatment approaches of lupus nephritis
2. Antibodies to DNA
3. Induction of cationic shift in IgG anti-DNA autoantibodies: Role of T helper cells with classical and novel phenotype in three models of lupus nephritis
4. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model
5. Comparison of the requirements for cognate T cell help for IgG anti-double-stranded DNA antibody production in vitro: T helper-derived lymphokines replace T cell cloned lines for B cells from NZB.H·2bm12 but not B6.H·2bm12 mice
6. Autoreactive T cells from MRL-Ipr/Ipr mice secrete multiple lymphokines and induce the production of IgG anti-DNA antibodies
7. Induction of immunological paralysis in two zones of dosage
8. Intravenous injection of soluble antigen induces thymic peripheral T-cell apoptosis
9. Immunologic tolerance for immune system-mediated diseases
10. Antigen-specific induction of peripheral T cell tolerance in vivo by codelivery of DNA vectors encoding antigen and Fas ligand
11. Animal models of myasthenia gravis
12. Murine models of systemic lupus erythematosus
13. The role of anti-idiotypic antibodies in the induction of experimental systemic lupus erythematosus in mice
14. MHC class II-restricted presentation of intracellular antigen
15. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells
16. Immunoglobulin-specific T-B cell interaction II. T cell clones recognize the processed form of B cells' own surface immunoglobulin in the context of the major histocompatibility complex class II molecule
17. Presentation of IgG2a antigens to class II-restricted T cells by stable transfected B lymphoma cells
18. Somatic origin of T-cell epitopes within antibody variable regions: Significance to monoclonal therapy and genesis of systemic autoimmune disease
19. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes
20. Processing and presentation of idiotypes to MHC-restricted T cells
21. Sequence analysis of peptides bound to MHC class II molecules
22. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles
23. Ig-specific T cell receptor-transgenic T cells are not deleted in the thymus and are functional in vivo
24. A peptide derived from an autoantibody can stimulate T cells in the (NZB x NZW) F1 mouse model of systemic lupus erythematosus
25. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus
26. T-cell determinants from autoantibody to DNA can upregulate systemic autoimmunity in murine SLE
27. Evidence for multiple mechanisms of polyclonal cell activation in murine lupus
28. Conditions that induce tolerance in murine CD4+ T cells
29. Designing consensus 'super-determinants' that strongly influence autoantibody production in lupus
30. Delaying SLE by immune tolerance to a consensus peptide results from interruption of T cell help triggered by multiple different peptides
31. A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZBxNZW)F1 mice
32. A peptide based on the CDR3 of an anti-DNA antibody of experimental SLE origin is also a dominant T cell epitope in (NZBxNZW)F1 lupus-prone mice
33. Prevention of systemic lupus erythmatosus-like disease in (NZB x NZW) f1 mice by treatment with CDR·1 and CDR·3 based peptides of pathogenic autoantibody
34. Nucleosome: A major immunogen for the pathogenic autoantibody-inducing T cells of lupus
35. Nucleosomal peptide epitopes for nephritis-inducing helper T cells of murine lupus
36. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: Tolerance spreading impairs pathogenic function of autoimmune T and B cells
37. Modulation of murine systemic lupus erythematosus with peptides based on complementary determining regions of a pathogenic anti-DNA monoclonal antibody
38. Characterization and role in experimental systemic lupus erythematosus of T cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody
39. Peptide inhibition of glomerular deposition of an anti-DNA antibody
40. Immunization with a peptide surrogate for double stranded DNA (dsDNA) induces autoantibody production and renal immunoglobulin deposition
41. Molecular analysis of the autoantibody response in peptide-induced autoimmunity
42. MHC class II-bound self peptides from autoimmune MRL/lpr mice reveal potential T cell epitopes for autoantibody production in murine systemic lupus erythematosus
43. Major peptide autoepitopes for nucleosome-specific T cells of human lupus
44. Human T cell responses to autoantibody variable region peptides
45. T cells of SLE patients recognize VH determinants of anti-dsDNA autoantibodies
46. T cell receptor beta-chain third complementarity determinant region gene usage is highly restricted among Sm-B autoantigen-specific human T cell clones derived from patients with connective tissue diseases
47. Analysis of T cell receptors specific for U1-70kD small nuclear ribonucleoprotein autoantigen: The alpha chain complementarity determinant region three is highly conserved among connective tissue disease patients
48. Neonatal peptide exposure can prime T cells, and upon subsequent immunization induce their immune deviation: Implications for antibody- vs T cell-mediated autoimmunity
49. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion
50. Reciprocal T·B determinant spreading develops spontaneously in murine lupus: Implications for pathogenesis
51. Immunization of mice with human 60-kd Ro peptides results in epitope spreading if the peptides are highly homologous between human and mouse
52. Evidence for polyclonal T cell activation in murine models of systemic lupus erythematosus
53. Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease
54. Self antigens and determinant spreading in systemic autoimmunity
55. Promiscuous presentation and recognition of nucleosomal autoepitopes in lupus Role of autoimmune T cell recepfor alpha chain
56. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment
57. Antigen-specific immunosuppression Nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats
58. Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen
59. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis
60. Treatment of rheumatoid arthritis with oral type II collagen: Results of a multicenter, double-blind, placebocontrolled trial
61. Neonatal tolerant immunity for vaccination against autoimmunity